These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35730388)

  • 1. No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART.
    Ward AR; Thomas AS; Stevenson EM; Huang SH; Keating SM; Gandhi RT; McMahon DK; Bosch RJ; Macatangay BJ; Cyktor JC; Eron JJ; Mellors JW; Jones RB;
    AIDS; 2022 Oct; 36(12):1617-1628. PubMed ID: 35730388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.
    Bedimo RJ; Mar H; Bosch RJ; Drechsler H; Cyktor JC; Macatangay BJC; Lalama C; Rinaldo C; Collier A; Godfrey C; Hogg E; Hensel C; Eron JJ; Mcmahon DK; Mellors JW; Tebas P; Gandhi RT;
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e27-e31. PubMed ID: 31335587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated With HIV DNA and HIV-Specific T-Cell Responses.
    Keating SM; Jones RB; Lalama CM; Bosch RJ; McMahon D; Hampton D; Cyktor J; Eron JJ; Mellors JW; Busch MP; Gandhi RT;
    J Acquir Immune Defic Syndr; 2019 Aug; 81(5):594-599. PubMed ID: 31045647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum globulin levels are associated with HIV reservoir size and immune restoration during long-term ART.
    Zhang Q; Jiao YM; Li G; Zhang LX; Gao L; Guo XY; Mijiti Z; Guo YT; Xu W; Huang HH; Wang FS
    HIV Med; 2023 Mar; 24(3):344-353. PubMed ID: 36101972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection.
    Mehraj V; Ramendra R; Isnard S; Dupuy FP; Lebouché B; Costiniuk C; Thomas R; Szabo J; Baril JG; Trottier B; Coté P; LeBlanc R; Durand M; Chartrand-Lefebvre C; Kema I; Zhang Y; Finkelman M; Tremblay C; Routy JP
    Front Immunol; 2019; 10():289. PubMed ID: 30846990
    [No Abstract]   [Full Text] [Related]  

  • 6. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.
    Gandhi RT; McMahon DK; Bosch RJ; Lalama CM; Cyktor JC; Macatangay BJ; Rinaldo CR; Riddler SA; Hogg E; Godfrey C; Collier AC; Eron JJ; Mellors JW;
    PLoS Pathog; 2017 Apr; 13(4):e1006285. PubMed ID: 28426825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Changes in Levels of Inflammation After Antiretroviral Treatment During Early HIV Infection in AIDS Clinical Trials Group Study A5217.
    Macatangay BJ; Yang M; Sun X; Morton J; De Gruttola V; Little S; Hogan C; Rinaldo CR;
    J Acquir Immune Defic Syndr; 2017 May; 75(1):137-141. PubMed ID: 28198712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.
    Ruggiero A; De Spiegelaere W; Cozzi-Lepri A; Kiselinova M; Pollakis G; Beloukas A; Vandekerckhove L; Strain M; Richman D; Phillips A; Geretti AM;
    EBioMedicine; 2015 Sep; 2(9):1153-9. PubMed ID: 26498496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.
    Jain V; Hartogensis W; Bacchetti P; Hunt PW; Hatano H; Sinclair E; Epling L; Lee TH; Busch MP; McCune JM; Pilcher CD; Hecht FM; Deeks SG
    J Infect Dis; 2013 Oct; 208(8):1202-11. PubMed ID: 23852127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy.
    Chiu CY; Schou MD; McMahon JH; Deeks SG; Fromentin R; Chomont N; Wykes MN; Rasmussen TA; Lewin SR
    Front Immunol; 2023; 14():1123342. PubMed ID: 37056754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid and lymphoid activation markers in AIDS and non-AIDS presenters.
    Iannetta M; Savinelli S; Rossi R; Mascia C; Marocco R; Vita S; Zuccalà P; Zingaropoli MA; Mengoni F; Massetti AP; Falciano M; d'Ettorre G; Ciardi MR; Mastroianni CM; Vullo V; Lichtner M
    Immunobiology; 2019 Mar; 224(2):231-241. PubMed ID: 30522891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
    Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN
    AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
    Khoury G; Fromentin R; Solomon A; Hartogensis W; Killian M; Hoh R; Somsouk M; Hunt PW; Girling V; Sinclair E; Bacchetti P; Anderson JL; Hecht FM; Deeks SG; Cameron PU; Chomont N; Lewin SR
    J Infect Dis; 2017 Mar; 215(6):911-919. PubMed ID: 28453847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High soluble CD163 levels correlate with disease progression and inflammation in Kenyan children with perinatal HIV-infection.
    Generoso M; Álvarez P; Kravietz A; Mwamzuka M; Marshed F; Ahmed A; Khaitan A
    AIDS; 2020 Jan; 34(1):33-38. PubMed ID: 31567161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.
    Sereti I; Krebs SJ; Phanuphak N; Fletcher JL; Slike B; Pinyakorn S; O'Connell RJ; Rupert A; Chomont N; Valcour V; Kim JH; Robb ML; Michael NL; Douek DC; Ananworanich J; Utay NS;
    Clin Infect Dis; 2017 Jan; 64(2):124-131. PubMed ID: 27737952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection.
    Amu S; Lantto Graham R; Bekele Y; Nasi A; Bengtsson C; Rethi B; Sorial S; Meini G; Zazzi M; Hejdeman B; Chiodi F
    Medicine (Baltimore); 2016 Jun; 95(23):e3738. PubMed ID: 27281071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red blood cell distribution width as an easily measurable biomarker of persistent inflammation and T cell dysregulation in antiretrovirally treated HIV-infected adults.
    Zhang Z; Chew GM; Shikuma CM; Gangcuangco LMA; Souza SA; Shiramizu B; Nakamoto BK; Gong T; Mannem SR; Mitchell BI; Kallianpur KJ; Ndhlovu LC; Chow DC
    HIV Clin Trials; 2018 Oct; 19(5):172-176. PubMed ID: 30422099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
    Li JZ; Segal FP; Bosch RJ; Lalama CM; Roberts-Toler C; Delagreverie H; Getz R; Garcia-Broncano P; Kinslow J; Tressler R; Van Dam CN; Keefer M; Carrington M; Lichterfeld M; Kuritzkes D; Yu XG; Landay A; Sax PE;
    Clin Infect Dis; 2020 Apr; 70(8):1636-1642. PubMed ID: 31131858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
    Tenorio AR; Zheng Y; Bosch RJ; Krishnan S; Rodriguez B; Hunt PW; Plants J; Seth A; Wilson CC; Deeks SG; Lederman MM; Landay AL
    J Infect Dis; 2014 Oct; 210(8):1248-59. PubMed ID: 24795473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Level of CD4
    Xia H; Jiang W; Zhang X; Qin L; Su B; Li Z; Sun J; Zhang Y; Zhang T; Lu X; Wu H
    Front Immunol; 2018; 9():616. PubMed ID: 29636753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.